ロード中...
BRAF突变型非小细胞肺癌免疫检查点抑制剂治疗进展
BRAF gene mutation is found in about 2%-4% of the patients with non-small cell lung cancer (NSCLC). This type of NSCLC is characterized by high malignancy, low efficacy of chemotherapy and poor prognosis. Although the combination treatment of BRAF inhibitor and MEK inhibitor has achieved remarkable...
保存先:
| 出版年: | Zhongguo Fei Ai Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国肺癌杂志编辑部
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6754571/ https://ncbi.nlm.nih.gov/pubmed/31526463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.09.06 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|